nach oben

Clinical & Experimental Metastasis

Erschienen in:

01.08.2010 | Research Paper

Proteomic strategies and challenges in tumor metastasis research

verfasst von: Petra Hudler, Masa Gorsic, Radovan Komel

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 6/2010

Einloggen, um Zugang zu erhalten

Abstract

The rapidly evolving field of proteomics offers new approaches to understanding the pathogenesis of cancer and metastatic disease. Although numerous tumor markers have been identified with different genomic methods in the past, most are either not specific or sensitive enough to be used in routine clinical setting. The rationale for proteomic profiling is based on the fact that proteins represent the dynamic state of the cells, reflecting pathophysiological changes in the disease more accurately than genomic and epigenetic alterations. Emerging proteomic techniques allow simultaneous assessment of a large number of proteins at one time. The study of protein profiles in complex systems, such as plasma, serum or tissues of cancer patients is likely to become valuable for monitoring the response of patients during treatment or for detecting recurrence of the disease.

Fokas E et al (2007) Metastasis: the seed and soil theory gains identity. Cancer Metastasis Rev 26(3–4):705–715CrossRefPubMed

Pantel K, Brakenhoff RH, Brandt B (2008) Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 8(5):329–340CrossRefPubMed

Sahai E (2005) Mechanisms of cancer cell invasion. Curr Opin Genet Dev 15(1):87–96CrossRefPubMed

Fidler IJ (2003) The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 3(6):453–458CrossRefPubMed

Langley RR, Fidler IJ (2007) Tumor cell–organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr Rev 28(3):297–321CrossRefPubMed

Chen YR et al (2006) Quantitative proteomic and genomic profiling reveals metastasis-related protein expression patterns in gastric cancer cells. J Proteome Res 5(10):2727–2742CrossRefPubMed

Ludwig JA, Weinstein JN (2005) Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 5(11):845–856CrossRefPubMed

Polanski M, Anderson NL (2006) A list of candidate cancer biomarkers for targeted proteomics. Biomark Insights 2:1–48

Cho WC (2007) Contribution of oncoproteomics to cancer biomarker discovery. Mol Cancer 6:25CrossRefPubMed

10.

Omenn GS (2006) Strategies for plasma proteomic profiling of cancers. Proteomics 6(20):5662–5673CrossRefPubMed

11.

Zieglschmid V, Hollmann C, Bocher O (2005) Detection of disseminated tumor cells in peripheral blood. Crit Rev Clin Lab Sci 42(2):155–196CrossRefPubMed

12.

Kumar S, Mohan A, Guleria R (2006) Biomarkers in cancer screening, research and detection: present and future: a review. Biomarkers 11(5):385–405CrossRefPubMed

13.

Alaiya A, Al-Mohanna M, Linder S (2005) Clinical cancer proteomics: promises and pitfalls. J Proteome Res 4(4):1213–1222CrossRefPubMed

14.

Cho WC, Cheng CH (2007) Oncoproteomics: current trends and future perspectives. Expert Rev Proteomics 4(3):401–410CrossRefPubMed

15.

Ciordia S, de Los Rios V, Albar JP (2006) Contributions of advanced proteomics technologies to cancer diagnosis. Clin Transl Oncol 8(8):566–580CrossRefPubMed

16.

Hanash SM, Pitteri SJ, Faca VM (2008) Mining the plasma proteome for cancer biomarkers. Nature 452(7187):571–579CrossRefPubMed

17.

Mani SA et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133(4):704–715CrossRefPubMed

18.

Pankova K et al (2010) The molecular mechanisms of transition between mesenchymal and amoeboid invasiveness in tumor cells. Cell Mol Life Sci 67(1):63–71CrossRefPubMed

19.

Steeg PS (2006) Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 12(8):895–904CrossRefPubMed

20.

Paterlini-Brechot P, Benali NL (2007) Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett 253(2):180–204CrossRefPubMed

21.

Steiniger SC et al (2008) Quantitative mass spectrometry identifies drug targets in cancer stem cell-containing side population. Stem Cells 26(12):3037–3046CrossRefPubMed

22.

Rosen JM, Jordan CT (2009) The increasing complexity of the cancer stem cell paradigm. Science 324(5935):1670–1673CrossRefPubMed

23.

Sullivan JP, Minna JD, Shay JW (2010) Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy. Cancer Metastasis Rev 29(1):61–72CrossRefPubMed

24.

Lu J et al (2010) Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients. Int J Cancer 126(3):669–683CrossRefPubMed

25.

Faca V, Krasnoselsky A, Hanash S (2007) Innovative proteomic approaches for cancer biomarker discovery. Biotechniques 43(3):279, 281–283, 285

26.

Petricoin E et al (2004) Clinical proteomics: revolutionizing disease detection and patient tailoring therapy. J Proteome Res 3(2):209–217CrossRefPubMed

27.

Pepe MS et al (2001) Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 93(14):1054–1061CrossRefPubMed

28.

National Comprehensive Cancer Network I (2007) NCCN clinical practice guidelines in oncology: prostate cancer v.1.2007

29.

American Cancer Society. Tumor Markers. http://www.cancer.org/Treatment/UnderstandingYourDiagnosis/ExamsandTestDescriptions/TumorMarkers/. Accessed 2 Jan 2010

30.

Lu M et al (2007) Proteomics and mass spectrometry for cancer biomarker discovery. Biomark Insights 2:347–360PubMed

31.

Mischak H et al (2009) Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: an update of recent developments. Mass Spectrom Rev 28(5):703–724CrossRefPubMed

32.

Van Eyk JE, Dunn MJ (2008) Clinical proteomics: from diagnosis to therapy. Wiley-VCH, Weinheim

33.

Liotta LA, Petricoin EF (2006) Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J Clin Invest 116(1):26–30CrossRefPubMed

34.

Omenn GS et al (2005) Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 5(13):3226–3245CrossRefPubMed

35.

de la Grange P et al (2010) Splicing factor and exon profiling across human tissues. Nucleic Acids Res 38(9):2825–2838CrossRefPubMed

36.

Dutertre M et al (2010) Exon-based clustering of murine breast tumor transcriptomes reveals alternative exons whose expression is associated with metastasis. Cancer Res 70(3):896–905CrossRefPubMed

37.

Qu X, Komatsu T (2010) Molecular capture in protein nanotubes. ACS Nano 4(1):563–573CrossRefPubMed

38.

Warder SE et al (2009) Reducing agent-mediated precipitation of high-abundance plasma proteins. Anal Biochem 387(2):184–193CrossRefPubMed

39.

Fang X, Zhang WW (2008) Affinity separation and enrichment methods in proteomic analysis. J Proteomics 71(3):284–303CrossRefPubMed

40.

Polaskova V et al (2010) High-abundance protein depletion: comparison of methods for human plasma biomarker discovery. Electrophoresis 31(3):471–482CrossRefPubMed

41.

Luchini A et al (2010) Nanoparticle technology: addressing the fundamental roadblocks to protein biomarker discovery. Curr Mol Med 10(2):133–141CrossRefPubMed

42.

Hortin GL (2006) The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin Chem 52(7):1223–1237CrossRefPubMed

43.

Lai X et al (2009) A proteomic workflow for discovery of serum carrier protein-bound biomarker candidates of alcohol abuse using LC-MS/MS. Electrophoresis 30(12):2207–2214CrossRefPubMed

44.

Lopez MF et al (2005) High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures. Clin Chem 51(10):1946–1954CrossRefPubMed

45.

Lowenthal MS et al (2005) Analysis of albumin-associated peptides and proteins from ovarian cancer patients. Clin Chem 51(10):1933–1945CrossRefPubMed

46.

Fredolini C et al (2009) Nanoparticle technology: amplifying the effective sensitivity of biomarker detection to create a urine test for hGH. Drug Test Anal 1(9–10):447–454CrossRefPubMed

47.

Longo C et al (2009) Core-shell hydrogel particles harvest, concentrate and preserve labile low abundance biomarkers. PLoS One 4(3):e4763CrossRefPubMed

48.

Luchini A et al (2008) Smart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradation. Nano Lett 8(1):350–361CrossRefPubMed

49.

Kolch W, Mischak H, Pitt AR (2005) The molecular make-up of a tumour: proteomics in cancer research. Clin Sci 108(5):369–383CrossRefPubMed

50.

Everley PA, Zetter BR (2005) Proteomics in tumor progression and metastasis. Ann N Y Acad Sci 1059:1–10CrossRefPubMed

51.

Ahram M et al (2002) Proteomic analysis of human prostate cancer. Mol Carcinog 33(1):9–15CrossRefPubMed

52.

O’Farrell PH (1975) High resolution two-dimensional electrophoresis of proteins. J Biol Chem 250(10):4007–4021PubMed

53.

Kleparnik K, Bocek P (2010) Electrophoresis today and tomorrow: helping biologists’ dreams come true. Bioessays 32(3):218–226CrossRefPubMed

54.

Gorg A, Weiss W, Dunn MJ (2004) Current two-dimensional electrophoresis technology for proteomics. Proteomics 4(12):3665–3685CrossRefPubMed

55.

Martin B et al (2008) Biological pathways contributing to organ-specific phenotype of brain metastatic cells. J Proteome Res 7(3):908–920CrossRefPubMed

56.

Hatakeyama H et al (2006) Protein clusters associated with carcinogenesis, histological differentiation and nodal metastasis in esophageal cancer. Proteomics 6(23):6300–6316CrossRefPubMed

57.

Han X, Aslanian A, Yates JR III (2008) Mass spectrometry for proteomics. Curr Opin Chem Biol 12(5):483–490CrossRefPubMed

58.

Pan S et al (2009) Mass spectrometry based targeted protein quantification: methods and applications. J Proteome Res 8(2):787–797CrossRefPubMed

59.

McAlister GC et al (2010) Analysis of tandem mass spectra by FTMS for improved large-scale proteomics with superior protein quantification. Anal Chem 82(1):316–322CrossRefPubMed

60.

Kicman AT, Parkin MC, Iles RK (2007) An introduction to mass spectrometry based proteomics-detection and characterization of gonadotropins and related molecules. Mol Cell Endocrinol 260–262:212–227CrossRefPubMed

61.

Wei J et al (2008) Overexpression of vimentin contributes to prostate cancer invasion and metastasis via src regulation. Anticancer Res 28(1A):327–334PubMed

62.

Liao CC et al (2010) Analysis of post-operative changes in serum protein expression profiles from colorectal cancer patients by MALDI-TOF mass spectrometry: a pilot methodological study. World J Surg Oncol 8:33CrossRefPubMed

63.

Schwartz SA et al (2005) Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Res 65(17):7674–7681PubMed

64.

Vydra J et al (2008) Two-dimensional electrophoretic comparison of metastatic and non-metastatic human breast tumors using in vitro cultured epithelial cells derived from the cancer tissues. BMC Cancer 8:107CrossRefPubMed

65.

De Bock M et al (2010) Challenges for biomarker discovery in body fluids using SELDI-TOF-MS. J Biomed Biotechnol 2010:906082PubMed

66.

Wang Q et al (2009) Limitations in SELDI-TOF MS whole serum proteomic profiling with IMAC surface to specifically detect colorectal cancer. BMC Cancer 9:287CrossRefPubMed

67.

Smith FM et al (2007) Combination of SELDI-TOF-MS and data mining provides early-stage response prediction for rectal tumors undergoing multimodal neoadjuvant therapy. Ann Surg 245(2):259–266CrossRefPubMed

68.

Qiu FM et al (2009) Mining novel biomarkers for prognosis of gastric cancer with serum proteomics. J Exp Clin Cancer Res 28:126CrossRefPubMed

69.

Asara JM et al (2008) A label-free quantification method by MS/MS TIC compared to SILAC and spectral counting in a proteomics screen. Proteomics 8(5):994–999CrossRefPubMed

70.

Faca VM et al (2008) Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains. PLoS One 3(6):e2425CrossRefPubMed

71.

Zhang DY et al (2009) Proteomics, pathway array and signaling network-based medicine in cancer. Cell Div 4:20CrossRefPubMed

72.

Bertone P, Snyder M (2005) Advances in functional protein microarray technology. FEBS J 272(21):5400–5411CrossRefPubMed

73.

Harmsen MM, De Haard HJ (2007) Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol 77(1):13–22CrossRefPubMed

74.

Kastelic D et al (2009) A single-step procedure of recombinant library construction for the selection of efficiently produced llama VH binders directed against cancer markers. J Immunol Methods 350(1–2):54–62CrossRefPubMed

75.

Hall DA, Ptacek J, Snyder M (2007) Protein microarray technology. Mech Ageing Dev 128(1):161–167CrossRefPubMed

76.

Osterfeld SJ et al (2008) Multiplex protein assays based on real-time magnetic nanotag sensing. Proc Natl Acad Sci USA 105(52):20637–20640CrossRefPubMed

77.

Fei YY et al (2008) A novel high-throughput scanning microscope for label-free detection of protein and small-molecule chemical microarrays. Rev Sci Instrum 79(1):013708CrossRefPubMed

78.

Grubb RL et al (2009) Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures. J Proteome Res 8(6):3044–3054CrossRefPubMed

79.

Tahara H et al (2009) Emerging concepts in biomarker discovery; the US–Japan workshop on immunological molecular markers in oncology. J Transl Med 7:45CrossRefPubMed

80.

Gulmann C et al (2009) Quantitative cell signalling analysis reveals down-regulation of MAPK pathway activation in colorectal cancer. J Pathol 218(4):514–519CrossRefPubMed

81.

Wulfkuhle JD et al (2008) Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res 7(4):1508–1517CrossRefPubMed

82.

He M, Taussig MJ (2001) Single step generation of protein arrays from DNA by cell-free expression and in situ immobilisation (PISA method). Nucleic Acids Res 29(15):E73CrossRefPubMed

83.

He M, Taussig MJ (2008) Production of protein arrays by cell-free systems. Methods Mol Biol 484:207–215CrossRefPubMed

84.

Sanchez-Carbayo M (2010) Antibody array-based technologies for cancer protein profiling and functional proteomic analyses using serum and tissue specimens. Tumour Biol 31(2):103–112CrossRefPubMed

85.

Wulfkuhle JD et al (2003) Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics 3(11):2085–2090CrossRefPubMed

86.

Nettikadan S et al (2006) Detection and quantification of protein biomarkers from fewer than 10 cells. Mol Cell Proteomics 5(5):895–901CrossRefPubMed

87.

Song S et al (2007) A cancer protein microarray platform using antibody fragments and its clinical applications. Mol Biosyst 3(2):151–158CrossRefPubMed

88.

Palagi PM et al (2006) Proteome informatics I: bioinformatics tools for processing experimental data. Proteomics 6(20):5435–5444CrossRefPubMed

89.

Blueggel M, Chamrad D, Meyer HE (2004) Bioinformatics in proteomics. Curr Pharm Biotechnol 5(1):79–88CrossRefPubMed

90.

Tan NC et al (2009) Application of multiple statistical tests to enhance mass spectrometry-based biomarker discovery. BMC Bioinformatics 10:144CrossRefPubMed

91.

Wang Y, Hanley R, Klemke RL (2006) Computational methods for comparison of large genomic and proteomic datasets reveal protein markers of metastatic cancer. J Proteome Res 5(4):907–915CrossRefPubMed

92.

Beretta L (2007) Proteomics from the clinical perspective: many hopes and much debate. Nat Methods 4(10):785–786CrossRefPubMed

93.

Espina V et al (2008) A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics 7(10):1998–2018CrossRefPubMed

Titel: Proteomic strategies and challenges in tumor metastasis research
verfasst von: Petra Hudler
Masa Gorsic
Radovan Komel
Publikationsdatum: 01.08.2010
Verlag: Springer Netherlands
Erschienen in: Clinical & Experimental Metastasis / Ausgabe 6/2010
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-010-9339-7

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Proteomic strategies and challenges in tumor metastasis research

Abstract

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2010

Functional genomics of endothelial cells treated with anti-angiogenic or angiopreventive drugs

Gene signature of the metastatic potential of cutaneous melanoma: too much for too little?

Lung cancer progression and metastasis from the prognostic point of view

Similar expression profiles of a core of genes and proteins in cells that have acquired a metastatic phenotype, genetically or by in vivo evolution

Genomics of metastatic progression

Childhood rhabdomyosarcoma metastatic to bone marrow presenting with disseminated intravascular coagulation and acute tumour lysis syndrome: review of the literature apropos of two cases

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie